Umeå University's logo

Purpose: To assess the effect of two high-oxygen epi-on PiXL treatments for low-grade myopia.

Methods: This prospective, randomized, intra-individually comparing, single-masked study included 23 healthy volunteers (46 eyes) aged 18-35 years with mild myopia, -0.75 to -2.50 D manifest refractive spherical equivalent (MRSE). One eye was randomized to a 4.0-mm homogenous treatment zone and the fellow eye to a 4.0-mm annular zone (16:40 min at 30 mW/cm(2), fluence 15 J/cm(2)). Uncorrected distance visual acuity (UDVA), MRSE, best spectacle-corrected visual acuity (BSCVA), Scheimpflug light scattering depths, mean keratometry (K-mean) and endothelial cell count (ECC) were assessed through 24 months.

Results: Similar improvements in UDVA were seen for the homogeneous and annular protocols at 1 month: -0.52 (-0.59, -0.39) and -0.49 (-0.59, -0.39) logMAR, respectively (medians and interquartile ranges, IQR), p = 0.91, and MRSE: +1.0 D (0.94, 1.31) and +1.0 D (0.69, 1.25), p = 0.17. Light scattering depths were 496 (465, 527) and 349 (247, 378) mu m, respectively, and the reduction in mean keratometry was -0.8 D (-1.1, -0.7) and 0 D (-0.1, 0.1), p < 0.001. The treatment effect remained stable throughout 24 months. At 1 week, the participants reported less ocular discomfort with the annular protocol. No reductions were seen in BSCVA or ECC. No adverse events were reported.

Conclusion: PiXL can reduce low-grade myopia and improve uncorrected vision in healthy eyes. The initial ocular discomfort may be reduced with an annular treatment zone. Further studies are needed to optimize PiXL treatment parameters.

Purpose: To compare two annular epithelium-on (epi-on) high oxygen photorefractive intrastromal cross-linking (PiXL) illuminations protocols for treatment of low-grade myopia.

Methods: In this randomized, single-masked, intra-individually comparative study, healthy individuals with bilateral low-grade myopia (manifest refractive spherical equivalent (MRSE) −0.75 diopters (D) to −2.50 D) were treated with high oxygen epi-on PiXL. One eye was randomized to receive pulsed accelerated 365-nm ultraviolet-A illumination in a central annular zone of 4.0 mm (1 second on, 1 second off; 30 mW/cm2), and the fellow eye in a 3.5 mm annular zone (0.5 second on, 1 second off; 45 mW/cm2). Uncorrected distance visual acuity (UDVA), MRSE, low-contrast visual acuity (LCVA), best spectacle corrected visual acuity (BSCVA), endothelial cell count (ECC) and Scheimpflug light scattering depths were assessed through 24-month follow-up.

Results: Twenty-seven participants (54 eyes) were included. The 3.5 mm protocol rendered less subjective ocular discomfort posttreatment and a larger improvement than the 4.0 mm protocol in UDVA: −0.52 (−0.72, −0.32) logMAR (medians and interquartile ranges, IQR) and −0.38 (−0.50, −0.22), p = 0.003 and MRSE: +1.25 D (0.75, 1.50) and +1.0 (0.75, 1.0), p = 0.037. The transient reduction in LCVA was larger with the 3.5 mm protocol (p < 0.01). No adverse events, and no reductions in ECC or BSCVA were noted.

Conclusion: Epi-on PiXL in high oxygen reduces myopia in healthy eyes. A larger reduction of myopia and less early posttreatment subjective ocular discomfort can be seen with a smaller treatment zone, but likely at the expense of a transient decrease in low-contrast visual acuity.

Purpose: To compare clinical outcomes of customized transepithelial (epi-on) corneal crosslinking (CXL) in high oxygen and customized CXL with epithelial removal (epi-off) in room air for keratoconus (KC).

Setting: Umeå University Hospital, Umeå, Sweden.

Design: Prospective, randomized, single-masked, intraindividually comparing study.

Methods: 32 participants with bilateral progressive KC were treated with bilateral customized topography-guided CXL, 30 mW/cm2; 7.2 to 15 J/cm2and were randomized to epi-on in one eye (32 eyes) and epi-off in the fellow eye (32 eyes). Uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA), maximal keratometry (Kmax), subjective ocular discomfort, low-contrast visual acuities (LCVAs) at 10% and 2.5% contrast, ocular and anterior corneal wavefront aberrations, manifest refractive spherical equivalent, endothelial cell count (ECC), and adverse events were assessed through 24 months.

Results: Both treatments showed improvements at 24 months in UDVA; -0.16 ± 0.24 (P <.001) and -0.13 ± 0.20 logMAR (P =.006), respectively, CDVA; -0.10 ± 0.11 (P <.001) and -0.10 ± 0.12 (P =.001), Kmax; -1.74 ± 1.31 (P <.001) and -1.72 ± 1.36 D (P <.001). LCVA 10% improved for both protocols (P <.001), but LCVA 2.5% improved for epi-on CXL only (P =.001). ECC was unaltered, and no adverse events occurred. The epi-on eyes had significantly less discomfort symptoms during the whole first week posttreatment (P <.05).

Conclusions: High-oxygen customized epi-on CXL is a viable alternative to room air customized epi-off CXL, with faster improvements in CDVA and LCVA and less early ocular discomfort.